InvestorsHub Logo
Followers 8
Posts 727
Boards Moderated 0
Alias Born 08/26/2018

Re: None

Tuesday, 10/15/2019 5:43:18 AM

Tuesday, October 15, 2019 5:43:18 AM

Post# of 426341
We we’re screwed by Goldman....deep sigh

Goldman starts Amarin at Neutral amid 'bullish' consensus expectations Goldman Sachs analyst Paul Choi initiated coverage of Amarin with a Neutral rating and 12-month price target of $17. The shares closed Monday up 23c to $15.45. The Street's "bullish" forecasts "necessitate near-perfect commercial execution," Choi tells investors in a research note. Pending FDA approval, Amarin is poised to start promoting Vascepa, which is already approved for patients with hypertriglyceridemia, with an expanded label in a much broader population, which could drive "significant" sales growth over the next several years, contends the analyst. However, he believes that consensus expectations have set a high bar for initial uptake relative to prior cardiovascular launches. This could limit share outperformance over the next 12 months, says Choi.

Read more at:
https://thefly.com/landingPageNews.php?id=2975248
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News